×

Al-Shifa Research Centre

 

Vision:

To be the centre of excellence for conducting world-class and creative bio-medical research activities to enhance the knowledge base and contribute towards improving the health care system and social advancement for the people of Pakistan.

Mission:

To emphasize rigorous research fundamentals while stimulating innovation and providing the highest quality research facilities in the institution.

Aim and Objectives

  • Work in coordination with the head of departments to identify areas of research
  • Provide operational support to the institution’s research activities/program and play a central role in facilitating the research outcome
  • Enhance the capacity building of trainees and students in academic research
  • Facilitating the faculty/postgraduate students to apply for research grants to HEC and other donor agencies
  • Find and explore the collaborations with national and international organizations
  • Establish and implement appropriate procedures and guidelines for monitoring research progress

Establishing a research centre shows that we really see value in bringing scientific evidence and also appreciate the importance of scientific culture. We believe that as long as we continue to work together as a team, we can give the very best of ourselves. We are dedicated to driving impact in critical spheres of health care to create impressive and meaningful breakthroughs and to fostering innovation through partnerships and team works. Al-Shifa Research Centre also prepares an annual research report covering the diverse array of all research activities done by the faculty, students, and trainees of Al-Shifa.

Prof. Dr. Ume Sughra
MBBS, MPH, FCPS (Comm. Med),
FRCP (Glasgow), MCPS-HPE
Director Research, Al-Shifa Research Centre
Professor of Public Health
E-mail: dr_sughra@yahoo.com


Clinical Trials

Sr. no. Trial Name Sponsor Status Report
1. A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO cell) for Prevention of COVID-19 Anhui Zhifei Longcom Biopharmaceutical Co., Ltd China Completed
Published in The New England Journal of Medicine
DOI: 10.1056/NEJMoa2202261
2. A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine when Administrated in Healthy Subjects aged 6 Months through 47 Months Seqirus Completed
3. (ALVOEYE) :A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age-related Macular Degeneration Alvotech Swiss AG On going
4. A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in Participants Aged 18 Years and Older who Completed Primary/1 Booster Dose(s) of SARS-CoV-2 Vaccination AIM Vaccine Co., Ltd.
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
LiveRNA Therapeutics Inc.
On going
5. A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants Bill & Melinda Gates Medical Research Institute On going
6. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Atea Pharmaceuticals, Inc. USA On going
7. A phase III, Randomized, Comparator-Controlled, Double-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Lot to Lot Consistency of Three Lots of a PIKA Rabies Vaccine (Vero cell) for human use, freeze-dried in Healthy Adults using a Post-Exposure Prophylaxis schedule Yisheng Biopharma (Singapore) Pte. Ltd. On going

Collaborators

Clinical Trial Team - QIVc (Seqirus)

Prof. Dr. Ume Sughra
Principal Investigator
Dr. Marriam Suleman
Sub-Investigator
Dr. Asmaa Riaz
Study Coordinator
Dr. Rasikh Arif
Unmasked Study Coordinator
Dr. Fatima Farahi
Masked Physician
Dr. Amna Shahid
Masked Physician
Dr. Ali Zeb Khan
Clinial Research Coordinator
Dr. Muhammad Hamza Rabbani
Masked Physician
Dr. Azalfa Malik
Masked Physician
Dr. Khizran Naseer
Masked Physician

Clinical Trial Team - AVT06 (Alvoeye)

Prof. Dr. Ume Sughra
Principal Investigator
Dr. Marriam Suleman
Sub-Investigator
Dr. Asmaa Riaz
Masked Study Coordinator
Dr. Rasikh Arif
Unmasked Study Coordinator
Dr. Ali Zeb Khan
Unmasked Pharmacist
Dr. Muhammad Hamza Rabbani
Masked Physician

Projects

Sr. no. Project Name Sponsor Principal Investigator Status
1. A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO cell) for Prevention of COVID-19 Anhui Zhifei Longcom Biopharmaceutical Co., Ltd China Prof. Dr. Ume Sughra Completed
Published in The New England Journal of Medicine
DOI: 10.1056/NEJMoa2202261
2. A project by WHO to evaluate the preparedness of public health facilities in Islamabad Capital Territory and Rawalpindi, Pakistan, for managing (potential) CBRN events and development of a standard national tool to evaluate hospital preparedness involving Emergency Departments (ED) as well as EMS providers’ readiness for CBRN events in Pakistan WHO EMRO, Pakistan Prof. Dr. Ume Sughra Completed
3. A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine when Administrated in Healthy Subjects aged 6 Months through 47 Months Seqirus IQVIA Solutions Pakistan (Pvt) Ltd Completed
4. (ALVOEYE) :A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age-related Macular Degeneration Alvotech Swiss AG Prof. Dr. Ume Sughra On going
5. A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in Participants Aged 18 Years and Older who Completed Primary/1 Booster Dose(s) of SARS-CoV-2 Vaccination AIM Vaccine Co., Ltd.
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
LiveRNA Therapeutics Inc.
Prof. Dr. Ume Sughra On going
6. A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants Bill & Melinda Gates Medical Research Institute Prof. Dr. Ume Sughra On going
7. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Atea Pharmaceuticals, Inc. USA Prof. Dr. Ume Sughra On going
8. A phase III, Randomized, Comparator-Controlled, Double-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Lot to Lot Consistency of Three Lots of a PIKA Rabies Vaccine (Vero cell) for human use, freeze-dried in Healthy Adults using a Post-Exposure Prophylaxis schedule Yisheng Biopharma (Singapore) Pte. Ltd. Prof. Dr. Ume Sughra On going

Annual Research Reports

2022

2021

2020

2019

2018

Events

Al-Shifa Research Centre

Contact Us

Al-Shifa Research Centre,
Pakistan Institute Of Ophthalmology (PIO),
Al-Shifa Trust Eye Hospital,
Jhelum Road, Rawalpindi, Pakistan.

Phone: 051-5487821-5 Ext 372
Email: dr_sughra@yahoo.com

Feedback us